Elafibranor is a Small Molecule owned by Genfit, and is involved in 26 clinical trials, of which 19 were completed, 4 are ongoing, and 3 are planned.

Elafibranor acts as an agonist of the peroxisome proliferator−activated receptor-alpha and peroxisome proliferator−activated receptor-delta. Peroxisome proliferator−activated receptors (PPARs) are nuclear receptors playing key roles in cellular processes regulating metabolic homeostasis, immune-inflammation, and differentiation. PPARα is most prominently expressed in the liver and is activated by hypolipidemic fibrates and controls the lipid flux in the liver by modulating fatty acid transport and β-oxidation, while improving plasma lipids by decreasing triglycerides and increasing high-density lipoprotein (HDL) cholesterol. PPARδ (also called PPARβ) regulates metabolism in liver and peripheral tissues. The drug candidate acts by reducing the liver fat content and improves insulin sensitivity, plasma lipids, and decreases γ-glutamyltransferase.

The revenue for Elafibranor is expected to reach a total of $2.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Elafibranor NPV Report.

Elafibranor is originated and owned by Genfit. Ipsen is the other company associated in development or marketing of Elafibranor.

Elafibranor Overview

Elafibranor (GFT-505) is under development for the treatment of colitis, non-alcoholic fatty liver disease, primary biliary cholangitis (PBC).  The drug candidate is administered orally as a coated tablet. It acts by targeting peroxisome proliferator-activated receptor (PPAR) alpha and PPAR-beta / PPAR- delta. The drug candidate was under development for dyslipidemia, abdominal obesity, type 2 diabetes, Crohn’s disease, insulin resistance and glucose intolerance, colitis and NAFLD/NASH-induced hepatocellular carcinoma (HCC). It was also underdevelopment for non-alcoholic steatohepatitis, liver fibrosis.

Ipsen Overview

Ipsen is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatic diseases. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

The company reported revenues of (Euro) EUR2,999.1 million for the fiscal year ended December 2021 (FY2021), an increase of 11.6% over FY2020. In FY2021, the company’s operating margin was 28.4%, compared to an operating margin of 19.7% in FY2020. In FY2021, the company recorded a net margin of 21.6%, compared to a net margin of 20.4% in FY2020.

Quick View – Elafibranor

Report Segments
  • Innovator
Drug Name
  • Elafibranor
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.